Aceragen (ACGN) Form 4 IDERA PHARMACEUTICALS / YOUSSEF EL ZEIN ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pillar Invest Corp

(Last) (First) (Middle)

C/O STUARTS CORPORATE SERVICES LTD.

KENSINGTON HOUSE, 69 DR. ROY'S DRIVE

(Street)

GEORGETOWN, GRAND CAYMAN E9 KY1-1104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDERA PHARMACEUTICALS, INC. [ IDRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2022		X		1,533,159	A	$0.01	7,266,954	I	By Pillar Partners Foundation, L.P. See Footnotes(1)(2)
Common Stock								2,304,180	I	By Pillar Pharmaceuticals 6, L.P. See Footnote(1)
Common Stock								386,110	I	By Abude Umari See Footnote(1)
Common Stock								26,308	I	By Youssef El Zein See Footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Prefunded Warrants	$0.01	09/22/2022		X			1,533,159	12/11/2020	(3)	Common Stock	1,533,159	$0.00	1,533,159	I	By Pillar Partners Foundation, L.P. See Footnote(2)

1. Name and Address of Reporting Person^*

Pillar Invest Corp

(Last) (First) (Middle)

C/O STUARTS CORPORATE SERVICES LTD.

KENSINGTON HOUSE, 69 DR. ROY'S DRIVE

(Street)

GEORGETOWN, GRAND CAYMAN E9 KY1-1104

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Pillar Partners Foundation, L.P.

(Last) (First) (Middle)

C/O STUARTS CORPORATE SERVICES LTD.

KENSINGTON HOUSE, 69 DR. ROY'S DRIVE

(Street)

GEORGETOWN, GRAND CAYMAN E9 KY1-1104

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Pillar Pharmaceuticals 6, L.P.

(Last) (First) (Middle)

C/O STUARTS CORPORATE SERVICES LTD.

KENSINGTON HOUSE, 69 DR. ROY'S DRIVE

(Street)

GEORGETOWN, GRAND CAYMAN E9 KY1-1104

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Umari Abude

(Last) (First) (Middle)

C/O STUARTS CORPORATE SERVICES LTD.

KENSINGTON HOUSE, 69 DR. ROY'S DRIVE

(Street)

GEORGETOWN, GRAND CAYMAN E9 KY1-1104

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

ZEIN YOUSSEF EL

(Last) (First) (Middle)

C/O STUARTS CORPORATE SERVICES LTD.

KENSINGTON HOUSE, 69 DR. ROY'S DRIVE

(Street)

GEORGETOWN, GRAND CAYMAN E9 KY1-1104

(City) (State) (Zip)

Explanation of Responses:

1. Pillar Invest Corporation ("Pillar GP") is the general partner of Pillar Pharmaceuticals 6, L.P. ("Pillar 6") and Pillar Partners Foundation, L.P. ("Pillar Partners", together with Pillar GP and Pillar 6, the "Pillar Funds"). Youssef El Zein and Abude Umari are directors of Pillar GP. Each of Pillar GP, Mr. El Zein and Mr. Umari disclaims Section 16 beneficial ownership of the securities beneficially owned by the Pillar Funds and this report shall not be deemed an admission that any of Pillar GP, Mr. El Zein or Mr. Umari is the Section 16 beneficial owner of any such securities, except to the extent of its or his pecuniary interest therein, if any, by virtue of its or his ownership interest in the Pillar Funds or Pillar GP, as applicable.

2. 1,533,159 of such warrants beneficially owned and exercised for shares of common stock by Pillar Partners, of which Pillar GP is the general partner (the "Pillar Partners Warrants"). Pillar GP disclaims Section 16 beneficial ownership of the Pillar Partners Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar Partners Warrants.

3. The Pre-funded Warrants have no expiration date.

Remarks:

	Pillar Invest Corporation, /s/ Youssef El Zein, Authorized Person	09/26/2022
	Pillar Partners Foundation, L.P., /s/ Youssef El Zein, Authorized Person	09/26/2022
	Pillar Pharmaceuticals, 6, L.P., /s/ Youssef El Zein, Authorized Person	09/26/2022
	/s/ Abude Umari	09/26/2022
	/s/ Youssef El Zein	09/26/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.